BioSyent

Name

BioSyent

Legal name

BioSyent Inc.

Website

https://biosyent.com

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Specialty pharmaceuticals
• Iron deficiency supplements
• Women's health products
• Oral health products
• Pharmaceutical distribution

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Products: Sale of prescription and over-the-counter pharmaceutical products including FeraMAX iron supplements, Tibelia, Inofolic, and other products marketed through Canadian pharmacies and healthcare providers.
2. Oral Health Products: Revenue from oral health products following the Oral Science acquisition, including dental hygiene and specialized oral health products distributed in Canada.
3. Thyconvi (Levothyroxine): BioSyent Pharma holds exclusive license rights to register, market, sell, and distribute Thyconvi across Canada, expanding into endocrinology therapeutic area.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

BioSyent is a Canadian specialty healthcare company that sources, in-licenses, acquires and further develops innovative pharmaceutical and oral health products. It commercializes a portfolio of prescription and OTC brands — including FeraMAX iron supplements, Inofolic for PCOS, Tibelia hormonal therapy, RepaGyn, Gelclair, Cathejell, Proktis-M and the newly approved Thyconvi levothyroxine oral solution — distributing them in Canada through a national sales team and pharmacies, with secondary international distribution in Latin America, Asia-Pacific and Africa.

Product overview

BioSyent is a specialty healthcare company operating a diversified portfolio of pharmaceutical and consumer health products across multiple therapeutic areas. The core platform consists of prescription and OTC products organized by therapeutic focus: iron health (FeraMAX line with Pd, Pd Maintenance 45, and Pd Powder 15 formulations), women's health (Inofolic for PCOS, Tibelia hormonal therapy), wound healing (RepaGyn and Proktis-M with hyaluronic acid), oncology supportive care (Gelclair), and anesthetics (Cathejell MD). The March 2026 acquisition of Oral Science expanded the portfolio into dental health products. A significant new launch is Thyconvi, the first Health Canada-approved levothyroxine oral solution for hypothyroidism, marking entry into endocrinology. The company markets approximately 10 approved products through community, specialty, and international commercial units.

Differentiator

Problem solved

Functional benefit

Brands

• FeraMAX: Over-the-counter iron supplement brand, Canada's top-recommended OTC iron supplement for 11 consecutive years. Includes FeraMAX Pd, FeraMAX Pd Maintenance 45, and FeraMAX Pd Powder 15 products.
• Thyconvi
• Inofolic
• RepaGyn
• Gelclair
• Cathejell
• Proktis-M
• Tibelia

Products and services

• FeraMAX Pd 150 mg Prescription-strength oral iron supplement using BioSyent's proprietary polydextrose-iron complex (PDIC) to deliver 150 mg of elemental iron for treating iron deficiency anemia in adults.
• FeraMAX Pd Maintenance 45 Chewable iron supplement with 45 mg elemental iron plus 75 mg vitamin C and 1000 mcg vitamin B12 for preventing iron deficiency anemia and supporting normal iron levels.
• FeraMAX Pd Powder 15 Pediatric iron supplement powder delivering 15 mg elemental iron per dose for infants and children ages 3 and up to prevent iron deficiency and anemia.
• Inofolic Myo-inositol and folic acid supplement for women with Polycystic Ovary Syndrome (PCOS), supporting menstrual cycle regulation, ovulation and fertility outcomes.
• Thyconvi (levothyroxine sodium oral solution) Levothyroxine sodium oral solution approved by Health Canada for managing hypothyroidism and thyroid-stimulating hormone suppression — the first levothyroxine oral solution available in Canada.
• Tibelia Hormonal therapy product generating $2.4 million in international sales in 2025, distributed across BioSyent's emerging-market commercial operations.
• RepaGyn Vaginal suppositories containing 5 mg hyaluronic acid per 2 g suppository for relieving vaginal dryness and promoting mucosal healing.
• Gelclair Oncology supportive care gel that forms a protective film when used as a mouthwash to relieve painful symptoms of oropharyngeal mucositis from medication, disease, radiotherapy, chemotherapy or oral surgery.
• Cathejell MD Topical 2% w/w lidocaine anesthetic gel for temporary numbing of skin prior to examinations and to relieve pain associated with bladder and urethral inflammation.
• Proktis-M Rectal suppositories containing 5 mg hyaluronic acid per 2 g suppository for promoting healing of the anus and rectum.
• Oral Science dental hygiene and oral health product line Line of dental hygiene and oral health products distributed to Canadian dental professionals through Oral Science Inc., the wholly-owned subsidiary acquired by BioSyent in March 2026.

Quantifiable outcome

• 23% revenue growth in FY 2025 to $43.1 million
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Oral Science Inc. (Acquired)coreStrategic or Co-development PartnerPrivately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec. Acquired for $25.5 million including cash, shares, earn-outs and royalties. Continues operating as standalone business unit with founding leadership team retained.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Others

• Cardinal Health: Major U.S. healthcare distributor and manufacturer; prior employer of BioSyent's VP & GM Marnie McCormick, who led marketing and product management for Cardinal Health Canada's large distribution business. Distribution model overlaps with BioSyent's pharmacy-channel GTM but at vastly larger scale.
• McKesson Canada: Canada's largest pharmaceutical distributor, serving the same Canadian pharmacy networks that BioSyent relies on for FeraMAX, Tibelia and other products. Functions as an indirect channel partner rather than a direct competitor but shapes the economics of BioSyent's distribution.

Direct peers

• Cipher Pharmaceuticals: Canadian specialty pharma company focused on dermatology, women's health, and hospital products through in-licensing and acquisition. Directly comparable to BioSyent's commercial-stage, niche-therapeutic strategy and TSX Venture listing.
• Acerus Pharmaceuticals: Canadian specialty pharma commercializing products in men's health, women's health, and endocrinology. Comparable in size, structure, and Canadian specialty pharma model; shares BioSyent's endocrinology and women's health therapeutic focus.
• Paladin Labs: Canadian specialty pharmaceutical company founded by Jonathan Ross Goodman (now Knight Therapeutics) focused on acquiring and licensing innovative products for Canadian and emerging markets. Provides a direct historical analogue to BioSyent's niche-licensing commercial model.
• Knight Therapeutics: Canadian specialty pharmaceutical company that acquires, in-licenses and markets innovative products across Latin America and other international markets. Closely mirrors BioSyent's commercial model of sourcing proven products globally and distributing through specialty channels, with a larger scale and similar therapeutic-area breadth.
• Searchlight Pharma: Privately-held Canadian specialty pharmaceutical company that in-licenses and markets women's health, dermatology and other niche products in Canada. Closely mirrors BioSyent's therapeutic portfolio emphasis on women's health and commercial-stage specialty model.
• HLS Therapeutics: Canadian specialty pharmaceutical company that acquires and commercializes late-stage products, primarily in CNS and cardiovascular. Similar in-licensing/M&A growth playbook and Canadian GTM to BioSyent, though focused on different therapeutic categories.

Broad incumbents

• Bausch Health Companies: Large Canadian-listed specialty pharma with diversified therapeutic portfolio including women's health, neurology, and dermatology. Much larger and broader in scope than BioSyent but operates in overlapping therapeutic categories through similar specialty-pharmacy channels.
• Tilray Brands: Canadian-listed company with pharmaceutical operations in addition to cannabis, distributing specialty health products through Canadian pharmacy and healthcare channels. Competes for capital and distribution shelf space but operates a much broader and less focused portfolio than BioSyent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/biosyentinc
• LinkedInlinkedin.com/company/3175508

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSyent